New title reflects growing role and responsibility in helping guide TGen research across multiple scientific disciplines
Author Archive: AZBio
NeoLight Raises $7M to Enable Home-Based Neonatal Care
PHOENIX, AZ / ACCESSWIRE / October 27, 2020 / Thank Covid-19: These days, hospital stays are risky, and space is at a premium. To get newborns and their parents home sooner, NeoLight, an Arizona State University spin-out, has raised $7 million to facilitate in-home neonatal care.
BIO Announces New Strategic Vision
BIO announces new, strategic direction that will help guide it to achieving long-term goals while maintaining responsiveness to changing political headwinds
HybridChart Announces Partnership with PointClickCare
Partnership to Integrate HybridChart’s Rounding and Workflow Solution with PointClickCare’s EHR PlatformContinue reading
AZBio Issues RFP for a Marketing Consultant to Support the AZAdvances Capital Campaign
Access to early stage growth capital is an ongoing challenge to the growth of Arizona’s Bioindustry. To address this challenge, AZBio, in partnership with the Opportunity Through Entrepreneurship Foundation and with support from a US. Economic Development Agency (EDA) grant has developed AZAdvances. The Marketing Consultant will work with the AZBio Team to inspire the community and engage support.Continue reading
AZBio Job Opportunity: Entrepreneurial Program Grants Administrator (Post-doc)
As part of its ongoing efforts to strengthen Arizona’s Bioscience and Medtech Entrepreneurial Ecosystem, AZBio encourages qualified post-doctorate applicants to apply to join our team as a Entrepreneurial Program Grants Administrator. This is a 1-year position.Continue reading
AZBio Job Opportunity: Entrepreneur in Residence
As part of its ongoing efforts to strengthen Arizona’s Bioscience and Medtech Entrepreneurial Ecosystem, AZBio encourages qualified applicants to apply to join our team as a Bioscience Entrepreneur-in-Residence (EIR).Continue reading
Online applications for the 2021 virtual KEYS program will open on November 1 and close December 6.
2021 KEYS PROGRAM | JUNE 7 – JULY 23, 2021
U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19
— Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States —
— Veklury Shortened Time to Recovery By Five Days in Hospitalized COVID-19 Patients —
Calviri, Inc. Receives Exclusive Patent License to Immunosignature Technology, Strengthening Its Disease Diagnostic Capabilities
Calviri, Inc., a biotech startup focused on ending deaths from cancer, announces that Skysong Innovations, the intellectual property management company for Arizona State University (“ASU”), granted Calviri an exclusive license to ASU’s Immunosignature patent portfolio. The portfolio consists of multiple granted and pending patents for the use and optimization of immunosignatures as an antibody-based diagnostic platform in the United States and the rest of the world.Continue reading